Compare CING & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CING | KNDI |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | China |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.3M | 67.8M |
| IPO Year | N/A | 2021 |
| Metric | CING | KNDI |
|---|---|---|
| Price | $4.49 | $0.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $34.50 | N/A |
| AVG Volume (30 Days) | ★ 419.3K | 136.8K |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.20 | $0.61 |
| 52 Week High | $11.89 | $1.77 |
| Indicator | CING | KNDI |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 51.03 |
| Support Level | $3.50 | $0.68 |
| Resistance Level | $6.67 | $0.79 |
| Average True Range (ATR) | 0.39 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 13.76 | 70.36 |
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.